Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Upadacitinib
Upadacitinib
AbbVie keen on JAK inhibitor despite safety concerns
BioPharma Dive
Tue, 09/12/17 - 04:22 pm
AbbVie
JAK inhibitors
Upadacitinib
ABT-494
rheumatoid arthritis
AbbVie reports two patient deaths in rheumatoid arthritis study
Yahoo/Reuters
Mon, 09/11/17 - 09:25 am
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
ABT-494
AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
Sun, 09/10/17 - 11:56 am
AbbVie
JAK inhibitors
clinical trials
atopic dermatitis
Upadacitinib
Sanofi
Regeneron
Dupixent
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
Endpoints
Thu, 09/7/17 - 09:46 am
AbbVie
ABT-494
atopic dermatitis
Upadacitinib
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Motley Fool
Fri, 06/23/17 - 03:37 pm
AbbVie
Humira
Upadacitinib
JAK inhibitors
autoimmune disease
First PhIII trial of AbbVie’s upadacitinib a success
Pharma Times
Sun, 06/11/17 - 05:34 pm
AbbVie
Upadacitinib
clinical trials
rheumatoid arthritis
Abbvie Vaults First Pivotal Hurdle With Oral RA Candidate
Seeking Alpha
Fri, 06/9/17 - 11:20 am
AbbVie
rheumatoid arthritis
Upadacitinib
AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
BioPharma Dive
Thu, 05/11/17 - 11:17 am
AbbVie
JAK inhibitors
Crohn's Disease
Upadacitinib
Pages
« first
‹ previous
1
2